Anti CD19/BCMA CAR Gene Therapy for Autoimmune Diseases
Status:
RECRUITING
Trial end date:
2029-08-31
Target enrollment:
Participant gender:
Summary
This is an open label, single-site, dose-escalation study in up to 18 participants with treatment of Refractory Autoimmune Diseases. This study aims to evaluate the safety and efficacy of the treatment with an Anti- CD19/BCMA CAR gene vector injection